Medicine and Dentistry
Therapeutic Procedure
100%
Neoplasm
56%
Inpatient
43%
Diseases
38%
Nodular Melanoma
35%
Malignant Neoplasm
35%
Breast Cancer
23%
Immunotherapy
21%
Overall Survival
21%
Surgery
19%
Radiation Therapy
17%
Follow up
16%
Recurrent Disease
15%
Ovarian Cancer
14%
Lung Cancer
14%
Evaluation Study
14%
Metastatic Carcinoma
13%
Oncology
13%
Clinical Trial
12%
Biological Marker
10%
Progression Free Survival
10%
Glioblastoma
10%
Cancer
9%
Retroperitoneal Lymph Node Dissection
9%
Metastatic Melanoma
9%
T Cell
9%
Cervical Cancer
9%
Prostate Cancer
9%
Adverse Event
8%
Lymph Node
8%
Gynecological Oncology
8%
Arm
7%
Brain Metastasis
7%
Non Small Cell Lung Cancer
7%
Infection
6%
Bevacizumab
6%
Krukenberg Tumor
6%
Quality of Life
6%
Sentinel Node
6%
Surgeon
6%
Sentinel Lymph Node
6%
Drug Megadose
5%
Immune Response
5%
Tumor Cell
5%
Phase II Trials
5%
Biopsy
5%
Odds Ratio
5%
Solid Malignant Neoplasm
5%
COVID-19
5%
In Vitro
5%
Cancer Cell
5%
Injury
5%
Symptoms
5%
Cisplatin
5%
Hazard Ratio
5%
Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
38%
Malignant Neoplasm
30%
Diseases
28%
Chemotherapy
20%
Melanoma
19%
Overall Survival
18%
Progression Free Survival
13%
Clinical Trial
12%
Breast Cancer
12%
Adverse Event
12%
Immunotherapy
12%
Glioblastoma
10%
Solid Malignant Neoplasm
10%
Lung Cancer
10%
Phase II Trials
9%
Biological Marker
9%
Ovary Cancer
9%
Prostate Cancer
8%
Bevacizumab
8%
Recurrent Disease
8%
Cisplatin
7%
Interleukin 2
7%
Uterine Cervix Cancer
7%
Non Small Cell Lung Cancer
7%
Cytokine
6%
Metastatic Melanoma
6%
Retinol
5%
Mouse
5%
Pharmacokinetics
5%
Placebo
5%
Remission
5%
Receptor
5%
Immunology and Microbiology
T Cell
25%
Immunotherapy
19%
Mouse
13%
Immune Response
10%
Monospecific Antibody
9%
Cytotoxic T-Cell
8%
Cytokine
8%
Overall Survival
8%
Vaccine Efficacy
7%
Tumor Cell
7%
T-Helper Cell
7%
Lymphocyte
5%
Macrophage
5%
Drug Megadose
5%
Tumor Antigen
5%
Interleukin 2
5%